Spectral AI, Inc.
No SEC Form 4 filings for $MDAI in the last 30 days.
See all $MDAI insider activity →Spectral AI (MDAI) showcased its FDA-cleared DeepView System for burn wound assessment at a conference. The company expects U.S. commercial sales by year-end 2026. Q2 2026 net loss narrowed to $4.2M, with revenue expected to reach $18.5M for the year. Stock closed at $1.55, down 2.52%.
Spectral AI, Inc. (MDAI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Spectral AI Announces 2026 Second Quarter Financial Results Company Continues to Advance Towards First Commercial Sales of the DeepView ® System for Burn Indication Strong Cash Position of $14.0 Million at June 30, 2026 DALLAS, TX – August 11, 2026 – Spectral AI, Inc
Spectral AI, Inc. (MDAI) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-99.1 2 ea029741201ex99-1.htm OFFER LETTER, BY AND BETWEEN DARCY BAJKO AND SPECTRAL AI, INC., DATED JULY 7, 2026 Exhibit 99.1 Darcy L. Bajko Cleveland, OH Re: Offer of Employment Dear Darcy, Spectral AI, Inc. (the “ Company ”) is pleased to make an offer of employment as Chief
Over the past 7 days, AlphAI's AI scored 1 news story mentioning MDAI (Spectral AI, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent MDAI coverage spans financial news, earnings and corporate actions.
Quarterly loss narrowed, cash remains healthy; potential upside if sales ramp up.
FDA clearance and a shift from reimbursed development to cost-share dynamics drive near-term margin pressure but improve commercialization visibility.
New CCO appointment and compensation terms are a modest, company-specific governance and operating-cadence signal, not a fundamental financial datapoint.
New commercial leadership and a stated push to close first commercial sales by year-end can improve near-term execution expectations.
FDA De Novo approval is a regulatory milestone, but the stock is trading down, implying investors are discounting near-term revenue ramp or pricing it as expected.
AlphAI scores every news story that mentions MDAI with an AI model for sentiment and relevance, and aggregates insider trades from Spectral AI, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Spectral AI (MDAI) showcased its FDA-cleared DeepView System for burn wound assessment at a conference. The company expects U.S. commercial sales by year-end 2026. Q2 2026 net loss narrowed to $4.2M, with revenue expected to reach $18.5M for the year. Stock closed at $1.55, down 2.52%.
2 min readSpectral AI, Inc. (MDAI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Spectral AI Announces 2026 Second Quarter Financial Results Company Continues to Advance Towards First Commercial Sales of the DeepView ® System for Burn Indication Strong Cash Position of $14.0 Million at June 30, 2026 DALLAS, TX – August 11, 2026 – Spectral AI, Inc
6 min readSpectral AI, Inc. (MDAI) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-99.1 2 ea029741201ex99-1.htm OFFER LETTER, BY AND BETWEEN DARCY BAJKO AND SPECTRAL AI, INC., DATED JULY 7, 2026 Exhibit 99.1 Darcy L. Bajko Cleveland, OH Re: Offer of Employment Dear Darcy, Spectral AI, Inc. (the “ Company ”) is pleased to make an offer of employment as Chief
2 min readSpectral AI, Inc. (Nasdaq: MDAI) appointed Darcy Bajko as Chief Commercial Officer effective July 31, 2026, to lead global sales for its FDA De Novo-cleared DeepView System for burn indication. The company said it aims to close its first commercial sales by year end 2026 and target adoption in US burn centers and emergency departments.
3 min readSpectral AI (MDAI) shares fell about 12% in Tuesday trading after the company said the U.S. FDA granted De Novo classification for its DeepView System, used in burn care. The company said the approval allows it to begin commercial distribution in the U.S. The stock was about $2.34, down from $2.68 at the prior close.
2 min readSpectral AI reported a 40.5% decrease in Q1 2026 research and development revenue, totaling $3.99 million, primarily due to a slowdown in BARDA contract activities as the base phase neared completion. Despite the revenue decline, the company saw an improvement in gross margin to 50.8%. Spectral AI posted a net loss of $3.41 million for the quarter, a significant shift from a net income in the prior year, attributed to lower revenue and a $1.0 million warrant liability loss, alongside increased interest and debt-discount amortization.
4 min readSpectral AI Inc. (NASDAQ:MDAI) released its Q4 2025 financial results, reporting a revenue beat of $3.85 million against an estimate of $2.98 million, but a wider non-GAAP loss per share of $0.11. Despite the loss, the stock saw gains in after-hours trading, driven by the revenue beat and a significantly strengthened cash position of $15.4 million. The company's focus remains on regulatory progress for its DeepView® System and its BARDA contract, with management providing a confident revenue guidance of $18.5 million for 2026, surpassing analyst estimates.
3 min readDALLAS, Nov. 19, 2025 ( GLOBE NEWSWIRE ) -- Spectral AI, Inc. ( NASDAQ:MDAI ) ( "Spectral AI" or the "Company" ) , an artificial intelligence ( AI ) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced its prominent role at the ...
3 min readImage source: The Motley Fool.Tuesday, November 11, 2025 at 5 p.m. ETNeed a quote from a Motley Fool analyst? Email pr@fool.comContinue reading ...
3 min readDALLAS, Sept. 19, 2025 ( GLOBE NEWSWIRE ) -- Spectral AI, Inc. ( Nasdaq: MDAI ) ( "Spectral AI" or the "Company" ) , an artificial intelligence ( AI ) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced it has been named to ...
3 min read
